What if we could better understand the effects of treatments on specific types of individuals, thereby allowing us to personalize drug treatments?
The Hol Picture
Our Insights on Real-World Evidence and Behavioral Health
Today marks World Mental Health Day, a day of recognition organized and sponsored by the World Health Organization. All month, we will also honor ADHD Awareness Month by looking back at some of the most important ADHD research we have done this year.
This year at the American Society of Clinical Psychopharmacology’s annual conference, I had the privilege to organize and chair a panel discussion on challenges and opportunities in leveraging real-world evidence to inform the development of new treatments in behavioral health.
Recently, FDA Commissioner Dr. Robert Califf spoke at Academy Health’s Health Datapalooza meeting and laid out several areas that the health care system must prioritize to improve outcomes and increase life expectancy. Many of his comments centered on better evidence, with a special emphasis on populations who are disproportionately impacted by negative outcomes.
Last month, I wrote an editorial in the Journal of Child Psychology & Psychiatry on the mental health crisis facing our nation’s children. A situation that was already becoming dire has only worsened during the COVID-19 pandemic—one meta-analysis found that the proportions of the world’s youth experiencing depressive symptoms or anxiety symptoms have doubled from pre-pandemic levels.